By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lixte Biotechnology 



East Setauket  New York    U.S.A.
Phone: Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported To Be A Potentiator Of Immunotherapy In An Animal Model 4/18/2017 12:37:31 PM
Late-Breaking Abstract On LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, In Combination With A PD-1 Inhibitor In An Animal Model To Be Presented At The AACR Annual Meeting 3/10/2017 11:05:00 AM
First-In-Human Assessment Of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published In Clinical Cancer Research 1/5/2017 9:19:47 AM
Dr. Stephen Forman Joins Lixte Biotechnology's Board Of Directors 6/7/2016 9:05:50 AM
Lixte Biotechnology's Lead Compound LB-100 Reported To Rapidly Improve Symptoms In A Rodent Model of Depression 2/3/2016 8:57:53 AM
Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock 1/25/2016 12:09:04 PM
Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock 3/18/2015 7:24:10 AM
Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies 2/25/2015 9:09:54 AM
Lixte Biotechnology's LB-100 Selected As One Of Informa And Kantar Health's 2014 Top 10 Most Interesting Oncology Projects To Watch 11/6/2014 10:39:39 AM
Lixte Biotechnology's Lead Compound Lb-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 6/18/2014 10:47:05 AM
1234
//-->